Chemotherapy-induced peripheral neuropathy common in early stage breast cancer
the ONA take:
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer and was strongly associated with docetaxel-based regimens, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the study, researchers from the Portuguese Institute of Oncology of Porto in Portugal sought to estimate the incidence of CIPN, identify factors associated with occurrence, and determine its impact on patient-reported outcomes.
Researchers enrolled 296 patients with incident breast cancer planning to receive chemotherapy. Patients were followed for 1 year.
Results showed that the cumulative incidence of CIPN in the first year after cancer diagnosis was 28.7% and more than 80% of participants were symptomatic 6 months after diagnosis.
The researchers found that patients who received docetaxel-based regimens were at a higher risk for developing CIPN, while alcohol consumption and diabetes were not significantly associated with CIPN.
“Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes,” the authors conclude.
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|